Larimar Therapeutics
phase dose exploration study for and cohorts | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
33 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
phase dose exploration study for and cohorts | Larimar Therapeutics
Related slides by other companies
BioNTech
Results
March 2022
phase expansion cohorts ongoing | BioNTech
Alkermes
Investor Day
March 2021
artistry phase efficacy expansion initiated following determination phase dose week lead in followed by combination of and either or cohorts a to a dose cohorts to dose phase efficacy expansion in solid tumors initiated at combination selected efficacy expansion in select solid tumors where previous responses were observed primary objectives safety and efficacy in combination with subcutaneous recommended phase dose administered once weekly administered once every three weeks secondary objectives include clinical profile and immunogenicity clinical pharmacodynamic effects all parts anti tumor activity phase and objective response rate and dor duration of response phase as fae | Alkermes
Arbutus Biopharma
Investor Presentation
January 2024
phase a clinical trial with | Arbutus Biopharma
ATAI
Investor Presentation
January 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights